Modulation of immune responses is highly relevant in tumor cell destruction. The present study is focused on the effect of Andrographis paniculata extract (APE) and its isolated compound andrographolide (ANDLE) on cellmediated immune responses in normal and tumor-bearing control animals. Treatment with APE and ANDLE significantly enhanced natural killer cell activity in normal (APE, 46.82% cell lysis; ANDLE, 40.79% cell lysis) and tumor-bearing animals (APE, 48.66% cell lysis; ANDLE, 42.19% cell lysis) on the fifth day, and it was observed earlier than in tumor-bearing control animals (12.89% cell lysis on day 9). Antibodydependent cellular cytotoxicity was also increased in APE (45.17% cell lysis on day 11) as well as ANDLE (39.92% cell lysis on day 11)-treated normal and tumor-bearing animals (APE, 47.39% cell lysis; ANDLE, 41.48% cell lysis on day 11) compared to untreated tumor-bearing control animals (maximum of 11.76% cell lysis on day 17). An early enhancement of antibody-dependent complement-mediated cytotoxicity was also observed by the administration of APE and ANDLE in normal as well as tumor-bearing animals. APE and ANDLE administration could significantly enhance the mitogen-induced proliferation of splenocyte, thymocyte, and bone marrow cells. Moreover, treatment of APE and ANDLE significantly elevated the production of interleukin-2 and interferon-γ γ in normal and Ehrlich ascites carcinomabearing animals.
Cancer continues to be a devastating disease that affects all societies. Conventional cancer therapies such as radiation and chemotherapy have a narrow margin of safety and may fail because of drug resistance and dose-limiting toxicities such as immunosuppression. 1 Tumor growth itself is associated with the onset of immunosuppression and concomitant inhibition of antitumor function of the host immune system. 2 Therefore, use of agents that modify the host immune system by inhibiting this immunosuppressive factors and reverse tumor-induced immunosuppression along with the conventional therapy may provide beneficial therapeutic effects.
Cell-mediated immune response plays a critical role in the elimination of tumors. 3 It confers immunity through the generation of various effector immune cells, which include antigen-specific CD4 + and CD8 + T lymphocytes and antigen nonspecific natural killer (NK) cells, macrophages, and so forth. 4 Decreased function or dysfunction of innate immune cells, especially cytotoxic T lymphocytes and NK cells, in cancer patients receiving chemotherapy and radiotherapy are responsible for their reduced immunity. 5 Hence, activation of immune responses in cancer patients is a vital step in countering the threat imposed by conventional therapies as well as by the tumor itself.
The use of herbal products is gaining increasing popularity as a way to assist tumor killing and to reduce the toxicity of therapeutic agents. 6, 7 Ayurveda, the Indian traditional system of medicine, which dates back many centuries, uses many herbal extracts to cure a variety of diseases including cancer. Andrographis paniculata is a medicinal herb belonging to the family Acanthaceae and is reported to have antidiabetic 8 and antithrombotic properties. 9 In addition, it also possesses hepatoprotective 10 and antipyretic activities. 11 Andrographolide, a diterpene lactone, the active component of this plant, has multiple pharmacological activities such as antiprotozoan activity and inhibitory activity on platelet aggregation. 12 It has also been demonstrated to inhibit the proliferation of various cancer cell lines. 13 It was reported earlier that Ehrlich ascites carcinoma (EAC) development is accompanied by hematopoietic suppression, splenomegaly, and production of a large amount of prostaglandin E, which is known to be a suppressor of hematopoiesis. 14, 15 In this study, we analyzed the effect of Andrographis paniculata extract (APE) and andrographolide (ANDLE) on NK cell activity, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent complement-mediated cytotoxicity (ACC). The effect of APE and ANDLE on serum interleukin (IL)-2 and interferon (IFN)-γ profiles in normal and EAC-bearing animals was also studied. Furthermore, we also analyzed the effect of APE and ANDLE on mitogen-induced proliferation of splenocyte, thymocyte, and bone marrow cells.
Materials and Methods
Cell Lines K-562 chronic myelogenic human leukemic cells were obtained from the National Centre for Cell Science (Pune, India). EAC cells were obtained from the Cancer Institute (Mumbai, India). Sheep red blood cells (SRBCs) were freshly collected in Alsever's solution from the slaughterhouse.
Animals
BALB/c mice (4-to 6-week-old males, weighing 15-20 g) were taken from the breeding section of Amala Cancer Research Centre and were housed in ventilated cages. They were fed with normal mouse chow and water ad libitum. All animal experiments were conducted according to the rules and regulations of the Animal Ethics Committee, Government of India.
Reagents
Animal tissue culture media DMEM and RPMI-1640 was procured from Hi-Media Laboratories (Mumbai, India). Fetal calf serum (FCS) was obtained from Biological Industries (Israel). Phytohemagglutinin (PHA) was obtained from Difco (Franklin Lakes, NJ). Concanavalin A (Con A) and poke weed mitogen (PWM) were purchased from Sigma (St Louis, Mo). PPO and POPOP were purchased from Sisco Research Lab (Mumbai, India). 3 H-thymidine and radioactive chromium (Na 2 CrO 4 ) were purchased from the Board of Radiation and Isotope Technology (Mumbai, India). Highly specific quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kits for mouse IL-2 and IFN-γ were procured from Pierce Biotechnology (Rockford, Ill). All other reagents were of analytical grade.
Preparation of the Plant Extract and Isolation of ANDLE
Air-dried whole plant was powdered and extracted using 70% ethanol by stirring overnight at 4°C. Supernatant was collected after centrifuging at 10 000 rpm at 4°C for 10 minutes. Ethanol was evaporated. The yield of the extract was 14%. Phytochemical analysis of the extract showed the presence of terpenoids and flavanoids. Andrographolide (Structure 1) was extracted from the dried plant powder according to method of Handa and Sharma. 16 Briefly, the whole plant material was dried, powdered, and extracted at room temperature successively with 4 × 40 L petroleum ether (60°C-80°C), chloroform, and methanol in soxhlet extraction assembly. The methanolic extract was concentrated, and activated charcoal (400 g) was added to it. After 24 hours, charcoal was filtered off, and the filtrate was concentrated under reduced pressure and left overnight for crystallization. The crystals were collected by filtration and purified by recrystallization. The isolated ANDLE was compared with an authentic sample by thin-layer chromatography. The purity of the isolated compound was determined by its melting point (230°C), ultraviolet absorption (maximum at 225 nm), 13 CNMR, and mass spectrum.
Administration of APE and ANDLE
For the animal administration, APE and ANDLE were dissolved in a minimum volume of ethanol and resuspended in 1% gum acacia and given intraperitoneally (ip) at a concentration of 10 mg/dose/animal and 500 µg/dose/animal, respectively.
Determination of Cell-Mediated Immune Responses in Normal and EAC-Bearing Animals
Five groups of BALB/c mice (12 per group) were used for this experiment. Group 1 and 2 animals were treated with 5 doses of APE (10 mg/animal/dose), and groups 3 and 4 received ANDLE (500 µg/animal/dose) for 5 consecutive days. EAC was induced to group 2 and 4 animals after the last dose of APE and ANDLE by injecting 1 × 10 6 EAC cells per animal intraperitoneally. Group 5 received EAC cells (1 × 10 6 cells/animal ip) alone and served as the untreated tumor-bearing control. One animal from each group was killed at different time points starting from 24 hours after tumor challenge; blood and spleen were collected. Serum was separated, heat inactivated at 56°C for 30 minutes, and used for the estimation of ACC. The spleen was processed to single-cell suspension in RPMI-1640 medium containing 10% FCS and used as effector cells for determining NK cell activity and ADCC.
Determination of NK Cell Activity
NK cell activity was determined by chromium release assay. 17 . Spleen cells (effector cells) from tumorbearing control, APE-treated, and ANDLE-treated mice were mixed with chromium-labeled K-562 cells (target cells) at a ratio of 100:1 (effector cell:target cell) in round-bottom titer plates and incubated at 37°C for 4 hours. Total as well as spontaneous release was determined by incubating the chromium-labeled target cells (K-562 cells) in the presence and absence of 1 N HCl in the same condition as above. After incubation, titer plates were centrifuged at 1500 rpm for 15 minutes, and supernatant was collected in radioimmunoassay vials. The released chromium in the supernatant was counted using a gamma ray counter. The entire test was done in triplicate. The percentage of cell lysis was calculated using the formula % Cell lysis = Experimental release − Spontaneous release × 100 Total release − Spontaneous release ADCC ADCC was determined by chromium release assay 17 using chromium-labeled SRBCs as the target cells and spleen from the tumor-bearing control as well as treated (APE and ANDLE) animals as the effector cells. The anti-SRBC antibody raised in rabbit was used as the source of antibody in ADCC assay. The target cells were incubated with effector cells at 37°C in 96-well, round-bottom titer plates in the presence of anti-SRBC for 4 hours. The released chromium in the culture supernatant was determined, and the percentage cell lysis was calculated as explained earlier.
ACC
The heat-inactivated serum, obtained from a previous experiment, was diluted with RPMI-1640 medium to a 1:1 dilution. The diluted serum (100 µl) was mixed with 1 × 10 4 EAC cells (100 µl). Fresh rabbit serum (1:10 diluted with medium) was added (50 µl) as a source of complement, and the final volume was made up to 2 mL with complete medium and incubated at 37°C for 3 hours. EAC cells alone, EAC cells with complements, and EAC cells with antibody (serum sample) without complement were kept as controls. After incubation cells were centrifuged, 1 mL of the supernatant was discarded, and the cytotoxicity was assessed by the trypan blue exclusion method. 18
Determination of Effect of APE and ANDLE on Spleen, Bone Marrow, and Thymus Blastogenesis
Three groups of BALB/c mice (4 animals/group) were used for this study. Group 1 and 2 animals were treated with APE (10 mg/dose/animal) and ANDLE (500 µg/dose/animal), respectively, for 5 consecutive days, keeping group 3 as a normal control. All the animals were killed 24 hours after the last dose of APE and ANDLE administration. Spleen and thymus were excised, and bone marrow cells taken from the femur in sterile condition were used for the blastogenesis assay.
Spleen Blastogenesis Assay
Spleen was processed aseptically and made into a single-cell suspension in RPMI-1640 medium containing 10% FCS, streptomycin, and penicillin and was cultured (5 × 10 4 cells) in 96-well, round-bottom titer plate in the presence and absence of various mitogens such as lipopolysaccharide (LPS; 10 µg/mL), concanavalin A (ConA; 10 µg/mL), phytohaemagglutinin (PHA; 2.5 µg/mL), and PWM (10 µg/mL) and incubated at 37°C for 48 hours. Eighteen hours before the termination of incubation, cells were radiolabeled by adding 1 µCi of 3 H-thymidine to each well and incubated for a further 18 hours. After completion of incubation, the titer plates were centrifuged at 1500 rpm for 10 minutes, supernatant was discarded, cells were dissolved in 100 µL NaOH (6 N), and incubation was continued for the next 2 hours at 37°C. After incubation, the entire content was added to 5 mL scintillation fluid and kept overnight in the dark. Radioactivity was measured as counts per minute (cpm) in a Rack beta liquid scintillation counter.
Thymus Blastogenesis Assay
Thymus from the above animals was also processed in sterile condition in RPMI-1640 medium containing 10% FCS and antibiotics, made into single-cell suspension and cultured (5 × 10 6 cells) in 96-well, round-bottom titer plates in the presence and absence of mitogens such as ConA (10 µg/mL), PHA (2.5 µg/mL), and PWM (10 µg/mL) for 48 hours at 37°C IN 5% CO 2 atmosphere. The cells were radiolabeled using 1 µCi of 3 H-thymidine per well. The radioactivity was measured using a Rack beta liquid scintillation counter as described above.
Bone Marrow Blastogenesis Assay
Bone marrow cells (5 × 10 4 cells) from the treated and untreated animals were cultured in the presence and absence of various mitogens such as LPS (10 µg/mL), ConA (10 µg/ml), PHA (2.5 µg/mL), and PWM (10 µg/mL) in a 96-well titer plate; the final volume was adjusted to 200 µL with RPMI medium and incubated for 48 hours. The rate of proliferation was analyzed by incorporating 1 µCi of 3 H-thymidine as described earlier.
Determination of the Effect of APE and ANDLE on IL-2 and IFN-γ γ Production in Normal and Tumor-Bearing Animals by ELISA
Six groups of BALB/c mice (6 animals/group) were used for this study. Group 1 animals were kept as normal controls, while groups 2 and 3 were treated with 5 doses of APE (10 mg/dose/animal) and ANDLE (500 µg/dose/animal), respectively, for 5 days. Animals in groups 4, 5, and 6 received EAC cells (1 × 10 6 cells) ip, of which groups 4 and 5 were treated with 5 doses of APE and ANDLE, respectively, simultaneously with tumor challenge, keeping group 6 as a tumor-bearing control. All the animals were killed on day 6 after tumor challenge, and blood was collected. Serum was separated from blood and used to estimate IL-2 and IFN-γ level by ELISA using highly specific mouse IL-2 and IFN-γ kits according to the manufacturer's protocol.
Statistical Analysis
The data were subjected to Student t test to determine significant differences between the groups. The values are expressed as mean ± standard deviation.
Results

Effect of APE and ANDLE on NK Cell Activity
The effect of APE and ANDLE on NK cell-mediated cytotoxicity in normal and tumor-bearing animals is shown in Figure 1 .
Administration of APE and ANDLE significantly enhanced the NK cell activity in normal as well as tumor-bearing animals, which commenced much earlier when compared to untreated tumor-bearing animals. Maximum NK cell cytotoxicity in APE (46.82% cell lysis) and ANDLE (40.79% cell lysis)-treated normal animals was observed on the fifth day after the last dose of APE and ANDLE, whereas NK cell-mediated target cell lysis in normal untreated animals was 1.65%. Peak NK cell activity in tumor-bearing animals on the fifth day after the administration of APE and ANDLE was 48.66% and 42.19%, respectively. In untreated tumor-bearing control animals, peak NK cell activity was observed only on the ninth day (12.89% cell lysis).
Effect of APE and ANDLE on ADCC
Administration of APE and ANDLE resulted in an increased ADCC in normal as well as tumor-bearing animals ( Figure 2 ). Treatment with APE (45.17% cell lysis) and ANDLE (39.92% cell lysis) significantly increased the ADCC with maximum target cell lysis on the 11th day after the last dose of APE and ANDLE. The maximum ADCC activity in EAC-bearing animals after the administration of APE and ANDLE was observed on day 11, while in untreated tumor-bearing animals, the peak ADCC activity was on day 15 (11.76% cell lysis). Figure 3 shows the effect of APE and ANDLE on ACC in normal and tumor-bearing animals. Administration of APE and ANDLE resulted in an increased ACC in normal as well as tumor-bearing animals. Normal animals showed enhanced ACC after administration of APE (25% cell lysis) and ANDLE (23% cell lysis). Tumor-bearing animals also showed an increased ACC activity with treatment of APE (27%) and ANDLE, (24%), with maximum cytotoxicity on day 17. But in tumor-bearing control animals, the maximum ACC activity (14% cell lysis) was observed on day 19. 
Effect of APE and ANDLE on ACC
Effect of APE and ANDLE on Splenocyte, Thymocyte, and Bone Marrow Proliferation
The effect of APE and ANDLE on splenocyte proliferation is given in Table 1 . There was a significant enhancement in the proliferation of spleen cells from APE-treated (6513.33 ± 52.31 cpm) and ANDLEtreated (6045.33 ± 58.53 cpm) treated mice in the presence of ConA (10 µg/mL) in comparison with spleen cells from untreated mice (1695.33 ± 52.39 cpm). Spleen cells from mice administered APE (4154.33 ± 33.50 cpm) and ANDLE (3724.76 ± 53.01 cpm) in the absence of mitogens also showed an increase in proliferation. Similarly, culturing of spleen from APE-treated (6281.33 ± 19.93 cpm) and ANDLE-treated (5871.33 ± 22 cpm) animals in the presence of PHA also showed an increase in the PHAmediated proliferation when compared to spleen cells from untreated normal animals. The presence of PWM also showed significant enhancement in proliferation of APE-treated (5726.66 ± 26.04 cpm) and ANDLE-treated (5362 ± 36.47 cpm) splenocyte.
Administration of APE (5314.66 ± 80.80 cpm) and ANDLE (4960 ± 41.86 cpm) also exhibited a synergistic mitogenic potential on spleen cells in the presence of LPS when compared to spleen cells from normal untreated mice in the presence of LPS (4015.66 ± 29.78 cpm). Table 2 shows the effect of APE and ANDLE on thymocyte proliferation in the presence and absence of various mitogens. APE (3892.66 ± 27.42 cpm) and ANDLE (3652.35 ± 39.19 cpm) administration stimulated thymocyte proliferation in the absence of mitogens. Culturing of thymus from APE-treated (6010 ± 35.25 cpm) and ANDLE-treated (5705 ± 39.38 cpm) animals in the presence of ConA showed an enhancement in proliferation when compared to thymus from untreated animals (4082 ± 31.5 cpm). Furthermore, PHA-induced thymocyte proliferation was also increased (3010.37 ± 24.74 cpm), and a synergistic effect was observed by the APE (4956.30 ± 32.56 cpm) and ANDLE (4641 ± 51.4cpm) administration. The effect of APE and ANDLE on bone marrow proliferation is given in Table 3 . Significant enhancement was observed in the ConA-induced proliferation of bone marrow cells from the APE-treated (2144.66 ± 41.6cpm) and ANDLE-treated (1904 ± 40.92 cpm) group compared to bone marrow cells from the normal group in the presence (1648.66 ± 50.16 cpm) and absence (1287 ± 33.17 cpm) of ConA. Administration of APE and ANDLE also enhanced the mitogenic potential of PWM (APE, 2355 ± 30.5 cpm; ANDLE, 2232.33 ± 44.97 cpm), PHA (APE, 3438 ± 28.9 cpm; ANDLE, 3270 ± 48.9 cpm), and LPS (APE, 3481 ± 36.06; ANDLE, 3309.3 ± 30.26 cpm) on bone marrow proliferation.
Effect of APE and ANDLE on Serum IFN-γ γ and IL-2 Level
The effect of APE and ANDLE on IFN-γ and IL-2 production is presented in Table 4 . IFN-γ production was significantly elevated in animals administered APE (3419.49 ± 121.58 pg/mL) and ANDLE (3149.15 ± 173.05 pg/mL) compared to normal animals (2956.78). Untreated EAC-bearing control animals showed decreased levels of IFN-γ (2162.71 ± 231.37 pg/mL) on the sixth day after tumor challenge, and it was significantly elevated to 3211.86 ± 111.46 pg/mL and 3016.94 ± 229.28 pg/mL by the administration of APE and ANDLE, respectively.
Similarly, the serum IL-2 level in normal mice was also found to be elevated after administration of APE (21.11 ± 1.14 pg/mL) and ANDLE (15.43 ± 0.63 pg/mL) in comparison with the normal untreated animals (7.87 ± 1.55 pg/mL). IL-2 production, which was reduced (5.83 ± 1.12 pg/mL) in the tumor-bearing untreated animals, was also considerably elevated by the administration of APE (16.24 ± 0.90 pg/mL) and ANDLE (15.07 ± 1.57 pg/mL) on the sixth day.
Discussion
Tumor progression requires suppression and/or evasion of the host immune system. 19 The immune status of the tumor microenvironment favors a polarized protumorigenic inflammatory state rather than one that represents antitumor immune responses because of the presence of impaired T lymphocytes and accumulation of activated myeloid suppressor cells, which enable the tumor cells to escape immune surveillance mechanisms. [20] [21] [22] Thus, the lethal efficacy with which tumor cells evade the immune system and other growth regulatory checks causes a major obstacle in cancer treatments. The role of various lymphocytes in tumor rejection is also well established. 23 NK cells, a Thymocytes from normal and treated animals were cultured in the presence and absence of mitogens (PHA and ConA), and the rate of proliferation was determined by H 3 -thymidine incorporation assay. All data are expressed as mean ± standard deviation. APE or ANDLE without mitogen was compared with normal without mitogen. APE or ANDLE with different mitogens (ConA/PHA) was compared with normal with respective mitogens. *P < .001. subpopulation of leukocytes, are potent effectors of the innate immune system and have also been implicated in tumor surveillance and tumor cell lysis in a variety of tumor cell lines and in multiple murine cancer models. 24, 25 They spontaneously recognize and kill malignant as well as virally infected cells without prior antigen sensitization. 26, 27 Functions of NK cells are regulated by an array of cell surface receptors that recognize different cellular ligands and can discriminate between target and nontarget cells. 25 Upon recognition of tumor cells, NK cells release the content of cytotoxic granules and also produce inflammatory cytokines, which are directly involved in the lysis of tumor cells. In our study, we found that NK cell activity in normal and tumor-bearing animals was significantly enhanced by the administration of APE and ANDLE, suggesting that they can effectively modulate the cellular arm of immune response. ADCC has been nominated as another mechanism of antitumor effects of lymphoid cell populations that are lacking surface immunoglobulin but bear Fc receptors such as NK cells, macrophages, neutrophils, and so forth. It can be mediated by contact of effector cells with the target cells through antibody. The crosslinking of Fc receptors (FcR, CD16) on effector cells to the Fc portion of antibody bound to target cell antigen leads to activation of effector cells to mediate killing of the target cell. 4 Administration of APE and ANDLE increased the ADCC activity, as observed from the increased lysis of target cells (SRBCs) in normal and tumor-bearing animals compared to tumor-bearing untreated control animals, revealing the immunopotentiating property of APE and ANDLE.
The complement system consists of about 30 serum proteins that are activated in response to various stimuli, known as the "complement cascade," ensuring the killing of altered cells. 4 In the present study, we found that treatment with APE and ANDLE significantly enhanced ACC (complement-mediated lysis of target cells) in normal and tumor-bearing animals compared to untreated tumor-bearing control animals, indicating the stimulation of antibody production by APE and ANDLE in vivo.
We further investigated the effect of APE and ANDLE on splenocyte, thymocyte, and bone marrow cell proliferation and found a significant increase in PHA-, PWM-, LPS-, and ConA-induced proliferation of bone marrow and splenocytes from APE-and ANDLE-treated animals in comparison with normal and non-mitogen-treated animals. Proliferation of lymphocytes and the subsequent release of immune active cytokines are important events in the generation of immune response. PHA and ConA are 2 T-cell mitogens. In our study, it was observed that PHA-and ConA-induced proliferation of splenocyte and thymocytes were significantly elevated compared to untreated animals, indicating that APE and ANDLE activate cell-mediated immune responses by stimulating T-lymphocyte proliferation, which in turn induces IL-2 production. PWM, a T-cell-mediated B-cell mitogen, also stimulated the splenocyte and bone marrow proliferation. Being the site for the production of a functionally mature immunocompetent pool of T cells, thymus plays a central role in the development of the host's immunocompetence. As observed from this study, APE and ANDLE increased thymocyte proliferation, suggesting their immunopotentiating efficacy. APE and ANDLE also effectively elevated the bone marrow proliferation induced by mitogens such as LPS, PHA, and ConA. Since all lymphocytes originate from the pleuripotent stem cells in bone marrow, this result suggests that APE and ANDLE are directly involved in the generation of lymphoid cells, which mediate the immune responses in the host.
Immune cells execute many of their functions through the production of various cytokines. IL-2 stimulates NK cell and T cell proliferation, 28 while IFN-γ, a key cytokine secreted by activated NK cells, interferes with the recognition and killing of target cells by upregulating class 1 major histocompatibility complex molecules and also exerts direct antitumor activity. 25 Administration of APE and ANDLE could significantly elevate the serum IL-2 and IFN-γ level in normal and tumor-bearing animals compared to untreated tumorbearing control animals, positively correlated with the increased NK cell and ADCC activity.
Based on these results, we conclude that APE and its isolated compound ANDLE are effective in activating the proliferation of lymphoid cells and effector cell functions by enhanced production of IL-2 Blood was collected from all the groups of animals on the sixth day after tumor challenge, serum was separated, and the IL-2 and IFNγ level was estimated by enzyme-linked immunosorbent assay kit. All data are expressed as mean ± standard deviation. Normal + APE and normal + ANDLE was compared with normal. EAC + APE and EAC + ANDLE were compared with EAC-bearing control. *P < .001.
and IFN-γ. Since a similar response was shown by crude extract of the plant and its isolated compound in NK cell activity, ADCC and ACC confirmed that ANDLE is the major constituent responsible for the augmentation of cell-mediated immune responses.
